Literature DB >> 2708010

HIV-2 in rhesus monkeys: serological, virological and clinical results.

D Dormont1, J Livartowski, S Chamaret, D Guetard, D Henin, R Levagueresse, P F van de Moortelle, B Larke, P Gourmelon, R Vazeux.   

Abstract

Diseases induced by animal retroviruses are not considered to be good models for the human acquired immunodeficiency syndrome (AIDS) at present. The lack of an animal model for the human immunodeficiency virus (HIV) infection presents a main problem in the complete understanding of the pathogenesis of HIV-mediated diseases. Because of the homologies between simian immunodeficiency virus (SIV) and HIV-2, we inoculated rhesus monkeys with HIV-2 and HIV-2 adapted in vitro to monkey cells. One of the ten animals inoculated developed clinical symptoms that might be related to the infection with HIV-2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2708010     DOI: 10.1159/000150125

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  12 in total

1.  Increased virus replication and virulence after serial passage of human immunodeficiency virus type 2 in baboons.

Authors:  Christopher P Locher; Stephanie A Witt; Brian G Herndier; Nancy W Abbey; Klara Tenner-Racz; Paul Racz; Nancy B Kiviat; Krishna K Murthy; Kathleen Brasky; Michelle Leland; Jay A Levy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: evidence of minimal genetic drift and low pathogenetic effects.

Authors:  G Franchini; P Markham; E Gard; K Fargnoli; S Keubaruwa; L Jagodzinski; M Robert-Guroff; P Lusso; G Ford; F Wong-Staal
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

Review 3.  Non-human primate models for AIDS vaccine research.

Authors:  Shiu-Lok Hu
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

4.  In vitro susceptibility of T lymphocytes from chimpanzees (Pan troglodytes) to human herpesvirus 6 (HHV-6): a potential animal model to study the interaction between HHV-6 and human immunodeficiency virus type 1 in vivo.

Authors:  P Lusso; P D Markham; S E DeRocco; R C Gallo
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques.

Authors:  Patricia Polacino; Kay Larsen; Lindsey Galmin; John Suschak; Zane Kraft; Leonidas Stamatatos; David Anderson; Susan W Barnett; Ranajit Pal; Kristen Bost; A H Bandivdekar; Christopher J Miller; Shiu-Lok Hu
Journal:  J Med Primatol       Date:  2008-12       Impact factor: 0.667

6.  Generation, characterization and cross-reactivities of monoclonal antibodies against the p24 core protein and the gp130 envelope glycoprotein of HIV-2ben.

Authors:  A C Faisst; A Otteken; S Nick; G Hunsmann
Journal:  Med Microbiol Immunol       Date:  1993-07       Impact factor: 3.402

7.  Evolution of the human immunodeficiency virus type 2 envelope gene in preimmunized and persistently infected rhesus macaques.

Authors:  M H Bäyon-Auboyer; F D Boussin; G Vogt; R Le Grand; B Vaslin; I Nicol-Jourdain; D Dormont
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

8.  Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.

Authors:  S Matsushita; S Matsumi; K Yoshimura; T Morikita; T Murakami; K Takatsuki
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Variability of the env gene in cynomolgus macaques persistently infected with human immunodeficiency virus type 2 strain ben.

Authors:  T Tolle; H Petry; B Bachmann; G Hunsmann; W Lüke
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

10.  Molecularly cloned simian immunodeficiency virus SIVagm3 is highly divergent from other SIVagm isolates and is biologically active in vitro and in vivo.

Authors:  M Baier; A Werner; K Cichutek; C Garber; C Müller; G Kraus; F J Ferdinand; S Hartung; T S Papas; R Kurth
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.